Notice of Proposed Sale · 144
Neurocrine Biosciences, Inc.
NBIXNASDAQEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- NEUROCRINE BIOSCIENCES, INC.
- Issuer CIK
- 0000914475
- SEC file number
- 000-22705
- Phone
- 8586177600
- Person for whose account securities are to be sold
- ERIC BENEVICH
- Relationships to issuer
- Officer
- Street
- 6027 Edgewood Bend Court
- City
- San Diego
- State / country code
- CA
- Postal code
- 92130
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common | 2,154 | 334,150.02 | 101,649,181 | 09/09/2026 | NASDAQ | Morgan Stanley Smith Barney LLC Executive Financial Services |
Broker / market maker — proposed row 1, entry 1
- Name
- Morgan Stanley Smith Barney LLC Executive Financial Services
- Street
- 1 New York Plaza
- Street (continued)
- 8th Floor
- City
- New York
- State / country code
- NY
- Postal code
- 10004
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Common | 09/09/2026 | Exercise of Stock Options | Issuer | 2,154 | N | 09/09/2026 | Cash |
Prior-sale reporting
- Nothing to report for the preceding three months
- Y
Notice signature
- Notice date
- 09/09/2026
- Signed
- /s/ Eric Benevich
- Plan adoption dates
- 06/10/2026
Company context
Neurocrine Biosciences is a leading biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering, developing and commercializing life-changing treatments for patients with under-addressed neurological, psychiatric, endocrine and immunological disorders. The company’s diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington’s disease, classic congenital adrenal hyperplasia, hyperphagia in patients with Prader-Willi syndrome, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For more than three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn, X, Facebook and YouTube. (*in collaboration with AbbVie)
Current securities
Recent company filings
- 10-Q filingNov 2, 2026
- Results of Operations and Financial ConditionNov 2, 2026
- SCHEDULE 13G/A - filed by JPMORGAN CHASE & CO regarding NEUROCRINE BIOSCIENCES INCOct 15, 2026
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsSep 28, 2026
- 4 filingSep 15, 2026